Cargando…
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection
The nasal mucosa is an important initial site of host defense against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, intramuscularly administered vaccines typically do not achieve high antibody titers in the nasal mucosa. We measure anti-SARS-CoV-2 spike immunoglobu...
Autores principales: | Aksyuk, Anastasia A., Bansal, Himanshu, Wilkins, Deidre, Stanley, Ann Marie, Sproule, Stephanie, Maaske, Jill, Sanikommui, Satya, Hartman, William R., Sobieszczyk, Magdalena E., Falsey, Ann R., Kelly, Elizabeth J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750884/ https://www.ncbi.nlm.nih.gov/pubmed/36610390 http://dx.doi.org/10.1016/j.xcrm.2022.100882 |
Ejemplares similares
-
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
por: Maaske, Jill, et al.
Publicado: (2023) -
LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)
por: Sobieszczyk, Magdalena, et al.
Publicado: (2021) -
Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Cohen, Taylor S., et al.
Publicado: (2022) -
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
por: Sobieszczyk, Magdalena E., et al.
Publicado: (2022) -
Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
por: Shetty, Arusha, et al.
Publicado: (2022)